Corvus' new Phase 1 atopic dermatitis data meet high expectations
Corvus 制药特应性皮炎 Phase 1 新数据符合高预期

Corvus Pharmaceuticals’ therapy for severe atopic dermatitis is heading to mid-stage trials this quarter following an update from an ongoing Phase 1 study that met analysts’ best-case scenario.
Corvus 制药治疗重度特应性皮炎的疗法在一项正在进行的 Phase 1 研究公布达到分析师最佳预期的最新结果后，将于本季度进入中期临床试验。